UK Pharmacy Zocor Faces “Major Challenges” Communicating Risk Factors
This article was originally published in The Tan Sheet
Executive Summary
Communicating appropriate cardiac risk factors for self-selection of statins still presents an obstacle for Zocor Heart-Pro (simvastatin 10 mg) despite the drug's pharmacy status, according to McNeil Europe VP-R&D Stephen Mann, MD
You may also be interested in...
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement
Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC